scholarly journals Kudzu Resistant Starch: An Effective Regulator of Type 2 Diabetes Mellitus

2021 ◽  
Vol 2021 ◽  
pp. 1-15
Author(s):  
Xinqi Song ◽  
Huanhuan Dong ◽  
Zhenzhong Zang ◽  
Wenting Wu ◽  
Weifeng Zhu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Gut Microbiota ◽  
Resistant Starch ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Underlying Mechanism ◽  
Insulin Synthesis

Kudzu is a traditional medicinal dietary supplement, and recent research has shown its significant benefits in the prevention/treatment of type 2 diabetes mellitus (T2DM). Starch is one of the main substances in Kudzu that contribute decisively to the treatment of T2DM. However, the underlying mechanism of the hypoglycemic activity is not clear. In this study, the effect of Kudzu resistant starch supplementation on the insulin resistance, gut physical barrier, and gut microbiota was investigated in T2DM mice. The result showed that Kudzu resistant starch could significantly decrease the value of fasting blood glucose and the levels of total cholesterol, total triglyceride, and high-density lipoprotein, as well as low-density lipoprotein, in the blood of T2DM mice. The insulin signaling sensitivity in liver tissue was analyzed; the result indicated that intake of different doses of Kudzu resistant starch can help restore the expression of IRS-1, p-PI3K, p-Akt, and Glut4 and thus enhance the efficiency of insulin synthesis. Furthermore, the intestinal microorganism changes before and after ingestion of Kudzu resistant starch were also analyzed; the result revealed that supplementation of KRS helps to alleviate and improve the dysbiosis of the gut microbiota caused by T2DM. These results validated that Kudzu resistant starch could improve the glucose sensitivity of T2DM mice by modulating IRS-1/PI3K/AKT/Glut4 signaling transduction. Kudzu resistant starch can be used as a promising prebiotic, and it also has beneficial effects on the gut microbiota structure of T2DM mice.

Health beneficial effects of resistant starch on diabetes and obesity via regulation of gut microbiota: a review

2020 ◽  
Vol 11 (7) ◽  
pp. 5749-5767
Author(s):  
Huicui Liu ◽  
Min Zhang ◽  
Qingyu Ma ◽  
Baoming Tian ◽  
Chenxi Nie ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Gut Microbiota ◽  
Resistant Starch ◽  
Beneficial Effects ◽  
Diabetes And Obesity

Resistant starch (RS) is well known to prevent type 2 diabetes mellitus (T2DM) and obesity.

scholarly journals Metformin reduces circulating malondialdehyde-modified low-density lipoprotein in type 2 diabetes mellitus

2014 ◽  
Vol 37 (4) ◽  
pp. 243 ◽  
Author(s):  
Masahiro Ohira ◽  
Takashi Yamaguchi ◽  
Atsuhito Saiki ◽  
Noriko Ban ◽  
Hidetoshi Kawana ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Hypoglycemic Agents ◽  
Low Density

Purpose: Type 2 diabetes is known to be associated with increasing cardiovascular mortality. Malondialdehyde-modified LDL (MDA-LDL) is an oxidized LDL and is increased in patients with diabetes or hypertriglyceridemia. Elevated MDA-LDL has been reported to be a risk factor of atherosclerosis or cardiovascular disease. Sitagliptin is a dipeptidyl peptidase-4 inhibitor and a new class of hypoglycemic agents. In this study, the effects of increasing the dose of metformin and add-on sitagliptin on MDA-LDL were examined in type 2 diabetes patients. Methods: Seventy patients with type 2 diabetes, inadequately controlled despite on-going treatment with metformin 500 mg/day, were enrolled in this randomized controlled trial. The patients received additional metformin (500 mg/day) or sitagliptin (50 mg/day) for 6 months, and changes in metabolic parameters including MDA-LDL were evaluated. Results: After 6 months of treatment, add-on sitagliptin (n=35) improved fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) to significantly greater extent than increasing the dose of metformin (n=35). There were no differences in total cholesterol and low-density lipoprotein cholesterol levels between two groups. MDA-LDL levels (mean±S.E.) decreased significantly with increasing the dose of metformin (from 94.40±6.35 to 77.83±4.74 U/L, P < 0.005), but remained unchanged with add-on sitagliptin treatment (from 89.94±5.59 to 98.46±6.78 U/L, p > 0.05). Multiple linear regression analysis identified increasing the dose of metformin treatment as the only independent factor associated with decreased MDA-LDL (β coefficient 0.367, P < 0.0119), and no significant correlation between change in MDA-LDL and fasting blood glucose or HbA1c. Conclusion: These results suggest that increasing the dose of metformin improves serum MDA-LDL levels in type 2 diabetes mellitus.

scholarly journals Association Between Pulse Index and Metabolic syndrome in Individuals with Type 2 Diabetes Mellitus: Outcome of a Twelve-Weeks Therapeutic Exercise

2009 ◽  
pp. 10-15
Author(s):  
Ade Fatai Adeniyi ◽  
Arinola O Sanya ◽  
A A Fasanmade ◽  
B Tijjani ◽  
A E Uloko
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Cardiovascular Fitness ◽  
Therapeutic Exercises

Background and Objective: Metabolic syndrome (MS) is an entity with clustering of cardiovascular risk factors and is associated with Type 2 Diabetes Mellitus (T2DM). Low level cardiovascular fitness is also associated with risk of T2DM. An association between Pulse Index (PI) and MS requires further description. This study sought to determine the association between PI and components of MS. Methods: Seventy-seven participants/subjects aged 48.6±6.52 years with T2DM were enrolled into the study at Aminu-Kano Teaching Hospital, Kano, Nigeria. PI and components of MS including Fasting Blood Glucose (FBG), Glycosylated Haemoglobin (HBAlc), High-Density Lipoprotein (HDL-CHOL), Triglycerides (TRIG.), Blood Pressure (BP) and obesity were assessed before and after twelve-week therapeutic exercises. Results: Inverse correlations were obtained for PI and each ofFBG (r=-0.45), HBAlc (r=-0.52), TRIG (r=-0.26), BP(r=-0.43/-0.32), Waist Circumference (r=-0.53), BMI (r=-0.79), blood pressure (r=-0.43/-0.32) except HDL-CHOL (r= 0.67), (P< 0.05 for all the subjects/participants). Conclusions: Low-levels of PI were associated with poor glycaemia, hypertension, obesity and dyslipidaemia. Therapeutic exercises aimed at improving cardiovascular fitness may have significant improvement on MS. which in turn aids the prevention of both T2DM and cardiovascular diseases. Keywords: Type 2 Diabetes Mellitus, Cardiovascular fitness, aerobic exercises, Pulse Index'

scholarly journals The single nucleotide polymorphisms rs11761556 and rs12706832 of the leptin gene are associated with type 2 diabetes mellitus in the iraqi population

2021 ◽  
pp. 5-5
Author(s):  
Karar Musafer ◽  
Fahrul Huyop ◽  
Mufeed Ewadh ◽  
Eko Supriyanto ◽  
Tahreer Al-Thuwaini ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Single Strand Conformation Polymorphism ◽  
Model Assessment ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide

This study was conducted to assess the potential association between leptin (LEP) gene polymorphisms and type 2 diabetes mellitus (T2DM) in Iraqi patients. Genomic DNA was extracted from 120 diabetic subjects and 100 controls. Three specific PCR fragments were designed to flank three highly frequent single nucleotide polymorphism (SNP)s within LEP, rs11761556, rs12706832 and rs2167270. The amplified loci were genotyped by PCR-single-strand conformation polymorphism (SSCP) followed by Sanger sequencing for representative genotypes. Logistic regression analysis was performed to detect the association between the targeted genetic variants and T2DM. PCR-SSCP genotyping showed three banding patterns for all three targeted SNPs. Individuals with the AA genotype in both rs11761556 and rs12706832 SNPs showed significantly higher (P<0.05) body mass index (BMI), waist circumference (WC), fasting blood glucose (FBG), hemoglobin A1c (HbA1c), homeostatic model assessment for insulin resistance (HOMA-IR), insulin, low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) values than those with other genotypes. Association analysis revealed that individuals with the A allele exhibited a greater risk of T2DM. Data of the present investigation indicated that both rs11761556 and rs12706832 SNPs exerted a noticeable association with T2DM. The study suggests implementing both rs11761556 and rs12706832 SNPs in the early detection of T2DM.

scholarly journals 16S rRNA Sequencing and Metagenomics Study of Gut Microbiota: Implications of BDB on Type 2 Diabetes Mellitus

Marine Drugs ◽  
2020 ◽  
Vol 18 (9) ◽  
pp. 469
Author(s):  
Liang Zhang ◽  
Jiao Luo ◽  
Xiangqian Li ◽  
Shuju Guo ◽  
Dayong Shi
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
16S Rrna ◽  
Gut Microbiota ◽  
Critical Role ◽  
Fasting Blood Glucose ◽  
Rrna Gene ◽  
Diabetic Mice

Gut microbiota has a critical role in metabolic diseases, including type 2 diabetes mellitus (T2DM). 3-bromo-4,5-bis(2,3-dibromo-4,5-dihydroxybenzyl)-1,2-benzenediol (BDB) is a natural bromophenol isolated from marine red alga Rhodomela confervoides. Our latest research showed that BDB could alleviate T2DM in diabetic BKS db mice. To find out whether BDB modulates the composition of the gut microbiota during T2DM treatment, 24 BKS db diabetic mice were randomly grouped to receive BDB (n = 6), metformin (n = 6), or the vehicle (n = 6) for 7 weeks in a blinded manner. Non-diabetic BKS mice (n = 6) were used as normal control. Diabetic mice treated with BDB or metformin demonstrated significant reductions in fasting blood glucose (FBG) levels compared with the vehicle-treated mice in the 7th week. Pyrosequencing of the V3–V4 regions of the 16S rRNA gene revealed the changes of gut microbiota in response to BDB treatment. The result demonstrated short-chain acid (SCFA) producing bacteria Lachnospiraceae and Bacteroides were found to be significantly more abundant in the BDB and metformin treated group than the vehicle-treatment diabetic group. Remarkably, at the genus levels, Akkermansia elevated significantly in the BDB-treatment group. Metagenomic results indicated that BDB may alleviate the metabolic disorder of diabetic mice by promoting propanoate metabolism and inhibiting starch and sucrose metabolism, amino sugar and nucleotide sugar metabolism. In conclusion, our study suggests that the anti-diabetic effect of BDB is closely related to the modulating structure of gut microbiota and the improvement of functional metabolism genes of intestinal microorganisms.

scholarly journals Study of fasting blood glucose, glycated hemoglobin and lipid profile in male and female type 2 diabetic patients

2020 ◽  
Vol 11 (1) ◽  
pp. 17-21
Author(s):  
Md Shajedul Islam ◽  
Farzana Akonjee Mishu ◽  
Mahbuba Khatun ◽  
Mohammad Amirul Islam
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Low Density

Background: Lipid abnormalities are more common in type 2 diabetes mellitus and are aggravated with poor glycaemic control. Lipid abnormalities play an important role in atherosclerosis, a leading cause of mortality in patients with diabetes mellitus. Thus there is a need to evaluate lipid profile and glycemic status in type 2 diabetes mellitus population and determine the major lipid risk factors for coronary artery disease. Present study focuses on the dyslipidemic pattern and glycemic status of male and female with type 2 diabetes mellitus. Methods: Total 270 patients with type 2 diabetes,age 30-60 years, both genderwere included for this crosssectional study which was carried out from January 2019 to December 2019at Bogura Diabetic Hospital, Bogura. A Structured questionnaire was prepared for each study subject after taking informed written consent. Detail personal, medical, family and socioeconomic history of study subjects were collected through history taking and review of clinical and biochemical records from the participants. Diabetic patients were diagnosed depending on history, clinical features and American Diabetes Association(ADA) criteria (2018). Fasting blood glucose, glycatedhaemoglobin (HbA1c)), fasting lipid profile were estimated in all study subjects by standard laboratory methods. Appropriate statistical tests were done. Results: Type 2 male diabetes mellitus participants showed mean fasting blood glucose, HbA1c, total cholesterol, triglyceride and low density lipoprotein cholesterol and high density lipoprotein cholesterol were 8.64 ± 3.38(mmol/L),7.86 ± 2.36(%), 233.09 ± 73.71, 198.19 ± 61.38, 152.98 ± 57.33 and 40.41 ± 5.44 (mg/ dl)respectively. Incase of female patients,fasting blood glucose, HbA1c, total cholesterol, triglyceride and low density lipoprotein cholesterol and high density lipoprotein cholesterol 8.59 ± 3.62(mmol/L),7.88 ± 2.496(%),215.899 ± 83.01, 186.18 ± 67.595, 139.10 ± 65.59 and 40.28 ± 5.66 mg/dlrespectively. There were statistically significant difference (p <0.05) of fasting blood glucose, fasting blood glucose, total cholesterol, triglyceride and low density lipoprotein cholesterol between male and female type 2 diabetic patients. Conclusion: Our study had shown that total cholesterol, triglycerides, and low-density lipoprotein levels were significantly increased in male type 2 diabetes mellitus patients, compared with female type 2 diabetes mellitus patients, while high-density lipoprotein had shown a statistically non-significant difference.This study demonstrated the existence of dyslipidemia in male diabetic population than female which is major risk factor for atherosclerosis and coronary artery disease. Birdem Med J 2021; 11(1): 17-21

Cinammon (Cinnamomum Spp.) and Type 2 Diabetes Mellitus

2019 ◽  
Vol 18 (3) ◽  
pp. 247-255
Author(s):  
Sierra-Puente D. ◽  
Abadi-Alfie S. ◽  
Arakanchi-Altaled K. ◽  
Bogard-Brondo M. ◽  
García-Lascurain M. ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Systematic Reviews ◽  
Meta Analysis ◽  
Fasting Blood Glucose ◽  
Tolerance Test ◽  
Oral Glucose ◽  
Key Aspects

Spices such as cinnamon (Cinnamomum Spp.) have been of interest due to their phytochemical composition that exert hypoglycemic effects with potential for management of type 2 diabetes mellitus (T2DM). We summarize data from 27 manuscripts that include, one book chapter, 3 review articles, 10 randomized controlled trials, 4 systematic reviews with meta-analysis, and 9 preclinical studies. The most frequently used cinnamon variety was Cinnamomum cassia rather than the Cinnamomum zeylanicum, whereas outcomes were defined as fasting blood glucose, glycated hemoglobin, and oral glucose tolerance test. A great variability in methodology such as different doses (from 120 mg to 6 g), duration of intervention, data retrieved and use of different concomitant medication, were found to be key aspects of most of trials and systematic reviews with meta-analysis available to date. Low quality studies have been made in most cases with a lot of heterogeneity clouding significance of results. More research needs to be done in order to yield accurate evidence for evidence-based recommendations. Its use is not currently a reliable nor advisable option for the treatment of T2DM.

Epigenetic modulation of autophagy genes linked to diabetic nephropathy by administration of isorhamnetin in Type 2 diabetes mellitus rats

Epigenomics ◽  
2021 ◽  
Author(s):  
Marwa Matboli ◽  
Doaa Ibrahim ◽  
Amany H Hasanin ◽  
Mohamed Kamel Hassan ◽  
Eman K Habib ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Fasting Blood Glucose ◽  
Light And Electron Microscopy ◽  
Lipid Profiles ◽  
Mirna Regulation ◽  
Protein Levels

Aim: To assess isorhamnetin efficacy for diabetic kidney disease in a Type 2 diabetes mellitus rat model, through investigating its effect at the epigenetic, mRNA and protein levels. Materials & methods: Type 2 diabetes mellitus was induced in rats by streptozotocin and high-fat diet. Rats were treated with isorhamnetin (50 mg/kg/d) for 4 or 8 weeks. Fasting blood glucose, renal and lipid profiles were evaluated. Renal tissues were examined by light and electron microscopy. Autophagy genes ( FYCO1, ULK, TECPR1 and  WIPI2) and miR-15b, miR-34a and miR-633 were assessed by qRT-PCR, and LC3A/B by immunoblotting. Results: Isorhamnetin improved fasting blood glucose, renal and lipid profiles with increased autophagosomes in renal tissues. It suppressed miRNA regulation of autophagy genes Conclusion: We propose a molecular mechanism for the isorhamnetin renoprotective effect by modulation of autophagy epigenetic regulators.

scholarly journals Gut microbiota influence in type 2 diabetes mellitus (T2DM)

Gut Pathogens ◽  
2021 ◽  
Vol 13 (1) ◽  
Author(s):  
A. L. Cunningham ◽  
J. W. Stephens ◽  
D. A. Harris
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Gut Microbiota ◽  
Potential Role ◽  
Evidence Base ◽  
Human Metabolism ◽  
Altered Glucose

AbstractA strong and expanding evidence base supports the influence of gut microbiota in human metabolism. Altered glucose homeostasis is associated with altered gut microbiota, and is clearly associated with the development of type 2 diabetes mellitus (T2DM) and associated complications. Understanding the causal association between gut microbiota and metabolic risk has the potential role of identifying susceptible individuals to allow early targeted intervention.

scholarly journals Role of TLR4/MyD88/NF-κB signaling in heart and liver-related complications in a rat model of type 2 diabetes mellitus

2021 ◽  
Vol 49 (3) ◽  
pp. 030006052199759
Author(s):  
Jiajia Tian ◽  
Yanyan Zhao ◽  
Lingling Wang ◽  
Lin Li
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Signaling Pathway ◽  
Rat Model ◽  
Fasting Blood Glucose ◽  
Diabetic Rats ◽  
Primary Response ◽  
Monocyte Chemoattractant Protein 1

Aims To analyze expression of members of the Toll-like receptor (TLR)4/myeloid differentiation primary response 88 (MyD88)/nuclear factor (NF)-κB signaling pathway in the heart and liver in a rat model of type 2 diabetes mellitus (T2DM). Our overall goal was to understand the underlying pathophysiological mechanisms. Methods We measured fasting blood glucose (FBG) and insulin (FINS) in a rat model of T2DM. Expression of members of the TLR4/MyD88/NF-κB signaling pathway as well as downstream cytokines was investigated. Levels of mRNA and protein were assessed using quantitative real-time polymerase chain reaction and western blotting, respectively. Protein content of tissue homogenates was assessed using enzyme-linked immunosorbent assays. Results Diabetic rats had lower body weights, higher FBG, higher FINS, and higher intraperitoneal glucose tolerance than normal rats. In addition, biochemical indicators related to heart and liver function were elevated in diabetic rats compared with normal rats. TLR4 and MyD88 were involved in the occurrence of T2DM as well as T2DM-related heart and liver complications. TLR4 caused T2DM-related heart and liver complications through activation of NF-κB. Conclusions TLR4/MyD88/NF-κB signaling induces production of tumor necrosis factor-α, interleukin-6, and monocyte chemoattractant protein-1, leading to the heart- and liver-related complications of T2DM.

Sign in / Sign up

Export Citation Format

Share Document